Lowest Price Guaranteed From USD 4,899
Published
July 2020
Pages
135
View Count
670
The “Congenital Hyperinsulinism Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Congenital Hyperinsulinism.
This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities.
One of the key objectives of the report was to estimate the existing market size and the future opportunity of therapies for congenital hyperinsulinism, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of the forecasted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2020-2030.
1. Preface
2. Executive Summary
3. Introduction
4. Current Market Landscape
4.1. Congenital Hyperinsulinism: Pipeline Review
4.1.1. Analysis by Type of Molecule
4.1.2. Analysis by Phase of Development
4.1.3. Analysis by Mechanism of Action
4.1.4. Analysis by Route of Administration
4.1.5. Analysis by Type of Therapy
4.2. Congenital Hyperinsulinism: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size and Location of Headquarters
4.2.3. Analysis by Geography
5. Company Profiles
6. KOL Analysis
7. Partnerships and Collaborations
8. Funding and Investment Analysis
9. Market Sizing and Opportunity Analysis
9.1. Congenital Hyperinsulinism Market: Distribution by Type of Therapy
9.2. Congenital Hyperinsulinism Market: Distribution by Type of Product
9.3. Congenital Hyperinsulinism Market: Distribution by Route of Administration
9.4. Congenital Hyperinsulinism Market: Distribution by Region
10. Executive Insights
11. Concluding Remarks
12. Appendix 1: Tabulated Data
13. Appendix 2: List of Companies and Organizations